stoxline Quote Chart Rank Option Currency Glossary
  
Vertex Pharmaceuticals Incorporated (VRTX)
475.79  -5.74 (-1.19%)    06-12 16:00
Open: 478
High: 481.71
Volume: 1,221,186
  
Pre. Close: 481.53
Low: 473.505
Market Cap: 122,779(M)
Technical analysis
2024-06-12 4:25:54 PM
Short term     
Mid term     
Targets 6-month :  568.14 1-year :  663.59
Resists First :  486.42 Second :  568.14
Pivot price 465.26
Supports First :  440.5 Second :  412.11
MAs MA(5) :  481.83 MA(20) :  459.51
MA(100) :  424.06 MA(250) :  388.22
MACD MACD :  16.3 Signal :  15.2
%K %D K(14,3) :  87.7 D(3) :  91.9
RSI RSI(14): 68.3
52-week High :  486.42 Low :  335.82
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ VRTX ] has closed below upper band by 33.8%. Bollinger Bands are 106.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 482.29 - 485.3 485.3 - 487.43
Low: 466.29 - 470.09 470.09 - 472.76
Close: 470.83 - 476.36 476.36 - 480.26
Company Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Headline News

Wed, 12 Jun 2024
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance

Wed, 12 Jun 2024
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Wed, 12 Jun 2024
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance

Wed, 12 Jun 2024
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Seven Eight Capital LP - Defense World

Tue, 11 Jun 2024
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Tue, 11 Jun 2024
Vertex Pharmaceuticals Incorporated (VRTX) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 258 (M)
Shares Float 257 (M)
Held by Insiders 0.1 (%)
Held by Institutions 95.7 (%)
Shares Short 3,770 (K)
Shares Short P.Month 4,030 (K)
Stock Financials
EPS 15.4
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 71.8
Profit Margin 39.4 %
Operating Margin 45.2 %
Return on Assets (ttm) 12.8 %
Return on Equity (ttm) 24.3 %
Qtrly Rev. Growth 13.3 %
Gross Profit (p.s.) 0
Sales Per Share 39.44
EBITDA (p.s.) 17.74
Qtrly Earnings Growth 56.5 %
Operating Cash Flow 3,940 (M)
Levered Free Cash Flow 3,310 (M)
Stock Valuations
PE Ratio 30.87
PEG Ratio 2.2
Price to Book value 6.62
Price to Sales 12.06
Price to Cash Flow 31.16
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android